Dominik Wernic
Overview
Explore the profile of Dominik Wernic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
224
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bijian K, Wernic D, Nivedha A, Su J, Lim F, Miron C, et al.
J Med Chem
. 2022 Feb;
65(4):3134-3150.
PMID: 35167283
Aurora kinases and protein kinase C (PKC) have been shown to be involved in different aspects of cancer progression. To date, no dual Aurora/PKC inhibitor with clinical efficacy and low...
2.
Chang C, Bijian K, Wernic D, Su J, da Silva S, Yu H, et al.
Autophagy
. 2019 Feb;
15(8):1376-1390.
PMID: 30773992
Patients with triple-negative breast cancer (TNBC) often have a poor prognosis largely due to lack of effective targeted therapy. Using a library of seleno-purines coupled to a high-throughput biochemical enzymatic...
3.
Fader L, Bailey M, Beaulieu E, Bilodeau F, Bonneau P, Bousquet Y, et al.
ACS Med Chem Lett
. 2016 Aug;
7(8):797-801.
PMID: 27563405
Optimization of pyridine-based noncatalytic site integrase inhibitors (NCINIs) based on compound 2 has led to the discovery of molecules capable of inhibiting virus harboring N124 variants of HIV integrase (IN)...
4.
Beaulieu P, De Marte J, Garneau M, Luo L, Stammers T, Telang C, et al.
Bioorg Med Chem Lett
. 2014 Dec;
25(2):210-5.
PMID: 25515558
A prodrug approach was developed to address the low oral bioavailability of a poorly soluble (<0.1μg/mL in pH 6.8 buffer) but highly permeable thumb pocket 1 HCV NS5B polymerase inhibitor....
5.
Beaulieu P, Anderson P, Bethell R, Bos M, Bousquet Y, Brochu C, et al.
J Med Chem
. 2014 Nov;
57(23):10130-43.
PMID: 25393851
The development of interferon-free regimens for the treatment of chronic HCV infection constitutes a preferred option that is expected in the future to provide patients with improved efficacy, better tolerability,...
6.
Fader L, Malenfant E, Parisien M, Carson R, Bilodeau F, Landry S, et al.
ACS Med Chem Lett
. 2014 Jun;
5(4):422-7.
PMID: 24900852
An assay recapitulating the 3' processing activity of HIV-1 integrase (IN) was used to screen the Boehringer Ingelheim compound collection. Hit-to-lead and lead optimization beginning with compound 1 established the...
7.
Stammers T, Coulombe R, Duplessis M, Fazal G, Gagnon A, Garneau M, et al.
Bioorg Med Chem Lett
. 2013 Nov;
23(24):6879-85.
PMID: 24176401
Optimization efforts on the anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors 1 and 2 resulted in the identification of multiple structural elements that contributed to improved cell culture...
8.
Waizenegger I, Gimenez-Abian J, Wernic D, Peters J
Curr Biol
. 2002 Aug;
12(16):1368-78.
PMID: 12194817
Background: Sister chromatid separation is initiated by separase, a protease that cleaves cohesin and thereby dissolves sister chromatid cohesion. Separase is activated by the degradation of its inhibitor securin and...
9.
Beaulieu P, Gillard J, Bailey M, Beaulieu C, Duceppe J, Lavallee P, et al.
J Org Chem
. 2001 Oct;
64(18):6622-6634.
PMID: 11674665
We have developed a highly convergent and stereoselective synthesis of BILA 2157 BS, a potent and orally active renin inhibitor. The synthesis proceeds in 15 distinct chemical steps (with several...
10.
Beaulieu P, Wernic D
J Org Chem
. 1996 May;
61(11):3635-3645.
PMID: 11667209
Enantiomerically pure N,N-dibenzyl-alpha-amino aldehydes reacted with (chloromethyl)lithium, generated in situ from bromochloromethane and lithium metal, to give predominantly erythro aminoalkyl epoxides. Treatment of the crude epoxides with aqueous hydrochloric acid...